KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Assets (2017 - 2025)

Moderna (MRNA) has disclosed Current Assets for 9 consecutive years, with $6.6 billion as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 31.74% to $6.6 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $6.6 billion, a 31.74% decrease, with the full-year FY2024 number at $8.1 billion, down 21.56% from a year prior.
  • Current Assets was $6.6 billion for Q3 2025 at Moderna, up from $6.2 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $16.4 billion in Q1 2022 to a low of $6.2 billion in Q2 2025.
  • A 5-year average of $11.3 billion and a median of $11.0 billion in 2021 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 155.18% in 2021, then plummeted 31.74% in 2025.
  • Moderna's Current Assets stood at $16.1 billion in 2021, then decreased by 16.43% to $13.4 billion in 2022, then dropped by 23.13% to $10.3 billion in 2023, then decreased by 21.56% to $8.1 billion in 2024, then decreased by 18.53% to $6.6 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Current Assets are $6.6 billion (Q3 2025), $6.2 billion (Q2 2025), and $8.1 billion (Q4 2024).